The Association between mrna Expression Levels of Ephx1 and Prognosis of Acute Myeloid Leukemia

The human epoxide hydrolase 1 (EPHX1) is a metabolism gene, which is responsible for the first phase of the xenobiotic metabolism. The product, microsomal epoxide hydrolase (mHE), plays an important role in the detoxification of carcinogenic polycyclic aromatic hydrocarbons. Many reports also have studied the correlation between EPHX1 gene polymorphisms and development and generation of cancers. However, few of studies on EPHX1 participating in chemotherapeutics metabolism were reported. The purpose of the present study was to evaluate the prognostic significance of the EPHX1gene expression in acute myeloid leukemia (AML). Using real time‑quantitative polymerase chain reaction (RT‑qPCR), mRNA expression levels of EPHX1gene was measured in bone marrow samples of newly diagnosed AML patients (n=46) and control group (n=12) without tumors. The levels expression of EPHX1 had a significant association with the treatment response and prognosis of AML patients. Additionally, the EPHX1 expression levels can aid for an improved understanding of the multidrug resistant mechanism in AML.

[1]  J. Castillo,et al.  Potential for improved survival with intensification of daunorubicin based induction chemotherapy in acute myeloid leukemia patients who do not receive transplant: A multicenter retrospective study. , 2015, Leukemia research.

[2]  Q. Wang,et al.  Upregulation of soluble epoxide hydrolase in proximal tubular cells mediated proteinuria-induced renal damage. , 2013, American journal of physiology. Renal physiology.

[3]  S. Marino,et al.  Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. , 2013, Pharmacogenomics.

[4]  P. Chauhan,et al.  High order interactions of xenobiotic metabolizing genes and P53 codon 72 polymorphisms in acute leukemia , 2012, Environmental and molecular mutagenesis.

[5]  S. Ohtake.  [Current treatment of acute myeloid leukemia]. , 2012, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[6]  Hongying Duan,et al.  Development of monoclonal antibodies to human microsomal epoxide hydrolase and analysis of "preneoplastic antigen"-like molecules. , 2012, Toxicology and applied pharmacology.

[7]  Zhi-jun Chen,et al.  System review and metaanalysis of the relationships between five metabolic gene polymorphisms and colorectal adenoma risk , 2012, Tumor Biology.

[8]  T. Tumer,et al.  Association between polymorphisms of EPHX1 and XRCC1 genes and the risk of childhood acute lymphoblastic leukemia , 2011, Archives of Toxicology.

[9]  Y. Min,et al.  A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia. , 2011, Blood.

[10]  J. Mulloy,et al.  Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects , 2011, International journal of hematology.

[11]  K. Guyton,et al.  Genetic polymorphism in metabolism and host defense enzymes: Implications for human health risk assessment , 2010, Critical reviews in toxicology.

[12]  F. Oesch,et al.  Epoxide hydrolases: structure, function, mechanism, and assay. , 2005, Methods in enzymology.

[13]  S. Z. Abdel‐Rahman,et al.  Human sensitivity to 1,3-butadiene: role of microsomal epoxide hydrolase polymorphisms. , 2001, Carcinogenesis.